TYME
Bedminster
About TYME
TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $155.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Feb 2021)
- Ticker: nasdaq:TYME
- Website: tymeinc.com
- Phone: +1 212-461-2315
Industries & Categories
Biotechnology, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tyme-175488 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.